Mesoblast MESO 深 滬
已收盤 10-31 16:00:00 美东时间
16.66
+0.230
+1.40%
華盛通- 最 高16.91
- 今 開16.50
- 成交量 14.62万股
- 最 低 16.3765
- 昨 收 16.43
- 總市值 21.32亿
- 52周最高 22.00
- 市盈率 靜 --
- 換手率 0.11%
- 52周最低 9.3613
- 委 比 43.99%
- 總股本 1.28亿
- 歷史最高 58.4372
- 量 比 1.22
- 振 幅 3.25%
- 歷史最低 1.9406
- 每 手 1
- 風險率 3.09%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Mesoblast Director Increases Shareholding Through Option Exercise
The latest update is out from Mesoblast Limited ( ($AU:MSB) ). Mesoblast Limite...
10-28 12:27
Mesoblast Limited’s 2025 Annual Report Highlights Corporate Governance Commitment
Mesoblast Limited ( ($AU:MSB) ) just unveiled an update. Mesoblast Limited has ...
10-27 09:27
Mesoblast Sees 69% Revenue Surge for Ryoncil® Amid Expanding Market Reach
The latest update is out from Mesoblast Limited ( ($AU:MSB) ). Mesoblast Limite...
10-20 09:47
Why CSX Shares Are Trading Higher By Over 4%; Here Are 20 Stocks Moving Premarket
Shares of CSX Corp (NASDAQ:CSX) rose sharply in pre-market trading after the co...
10-17 17:55
JPMorgan Chase & Co. Ceases Substantial Holding in Mesoblast Limited
Mesoblast Limited ( ($AU:MSB) ) has issued an announcement. JPMorgan Chase &...
10-15 05:55
Mesoblast reports Q2 revenue surge of 66% on strong Ryoncil sales
Mesoblast (OTCPK:MEOBF) reported US$21.9M in gross revenue for the quarter ended September 30, 2025. This marks a 66% increase compared to the previous quarter. Growth driven by strong sales of Ryonci...
10-07 12:34
Ryoncil® Revenues Increase 66% in Second Quarter Post Launch
Mesoblast Limited reported a 66% increase in Q3 2025 revenue for Ryoncil® to $21.9 million, driven by strong adoption and reimbursements. Ryoncil® is the first FDA-approved mesenchymal stromal cell (MSC) therapy for children under 12 with steroid-refractory acute graft-versus-host disease. The company attributes growth to the permanent J-Code assignment by CMS. Mesoblast focuses on allogeneic cellular medicines for inflammatory diseases with a ro...
10-06 23:24
Mesoblast Shares Are Rising Higher: What's Behind The Move?
Mesoblast Limited (NASDAQ:MESO) shares are trading higher on Friday after the company announced that Ryoncil received a J-Code from the United States Medicare & Medicaid Services, streamlining billing and payment processes for the product.
10-04 03:50
White Mountains Insurance, Rumble, Mesoblast And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Dow Jones index gaining more than 350 points ...
10-03 22:36
Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access
On October 1, 2025, Mesoblast Limited announced that a permanent J-Code (J3402) for Ryoncil® (remestemcel-L-rknd) became active, simplifying billing and reimbursement processes under U.S. Medicare & Medicaid Services (CMS). This milestone enhances access to Ryoncil®, the first FDA-approved mesenchymal stromal cell (MSC) product for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children. Mesoblast CEO Dr. Silviu Itescu emphasize...
10-03 01:04
